 Lysophospholipids
"Lysophospholipids" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Derivatives of PHOSPHATIDIC ACIDS that lack one of its fatty acyl chains due to its hydrolytic removal.
| Descriptor ID |
D008246
|
| MeSH Number(s) |
D10.570.755.375.760.550
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Lysophospholipids".
Below are MeSH descriptors whose meaning is more specific than "Lysophospholipids".
This graph shows the total number of publications written about "Lysophospholipids" by people in this website by year, and whether "Lysophospholipids" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2000 | 2 | 0 | 2 | | 2001 | 0 | 1 | 1 | | 2004 | 1 | 0 | 1 | | 2005 | 0 | 1 | 1 | | 2006 | 0 | 1 | 1 | | 2007 | 1 | 1 | 2 | | 2008 | 2 | 1 | 3 | | 2009 | 0 | 1 | 1 | | 2010 | 0 | 1 | 1 | | 2011 | 0 | 1 | 1 | | 2012 | 0 | 1 | 1 | | 2013 | 2 | 1 | 3 | | 2014 | 0 | 2 | 2 | | 2015 | 0 | 2 | 2 | | 2016 | 1 | 1 | 2 | | 2017 | 1 | 0 | 1 | | 2018 | 1 | 2 | 3 | | 2019 | 1 | 0 | 1 | | 2020 | 1 | 1 | 2 | | 2021 | 1 | 1 | 2 | | 2022 | 1 | 2 | 3 | | 2023 | 1 | 2 | 3 | | 2024 | 1 | 1 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Lysophospholipids" by people in Profiles.
-
Mondal K, Del Mar NA, Gary AA, Grambergs RC, Yousuf M, Tahia F, Stephenson B, Stephenson DJ, Chalfant CE, Reiner A, Mandal N. Sphingolipid changes in mouse brain and plasma after mild traumatic brain injury at the acute phases. Lipids Health Dis. 2024 Jun 27; 23(1):200.
-
Danielson SM, Lefferts AR, Norman E, Regner EH, Schulz HM, Sansone-Poe D, Orlicky DJ, Kuhn KA. Myeloid Cells and Sphingosine-1-Phosphate Are Required for TCRa? Intraepithelial Lymphocyte Recruitment to the Colon Epithelium. J Immunol. 2024 Jun 01; 212(11):1843-1854.
-
Turner JA, Fredrickson MA, D'Antonio M, Katsnelson E, MacBeth M, Van Gulick R, Chimed TS, McCarter M, D'Alessandro A, Robinson WA, Couts KL, Pelanda R, Klarquist J, Tobin RP, Torres RM. Lysophosphatidic acid modulates CD8 T cell immunosurveillance and metabolism to impair anti-tumor immunity. Nat Commun. 2023 06 03; 14(1):3214.
-
Hay A, Nemkov T, Gamboni F, Dzieciatkowska M, Key A, Galbraith M, Bartsch K, Sun K, Xia Y, Stone M, Busch MP, Norris PJ, Zimring JC, D'Alessandro A. Sphingosine 1-phosphate has a negative effect on RBC storage quality. Blood Adv. 2023 04 25; 7(8):1379-1393.
-
Torres RM, Turner JA, D'Antonio M, Pelanda R, Kremer KN. Regulation of CD8 T-cell signaling, metabolism, and cytotoxic activity by extracellular lysophosphatidic acid. Immunol Rev. 2023 08; 317(1):203-222.
-
Tanaka S, Zheng S, Kharel Y, Fritzemeier RG, Huang T, Foster D, Poudel N, Goggins E, Yamaoka Y, Rudnicka KP, Lipsey JE, Radel HV, Ryuh SM, Inoue T, Yao J, Rosin DL, Schwab SR, Santos WL, Lynch KR, Okusa MD. Sphingosine 1-phosphate signaling in perivascular cells enhances inflammation and fibrosis in the kidney. Sci Transl Med. 2022 08 17; 14(658):eabj2681.
-
Kremer KN, Buser A, Thumkeo D, Narumiya S, Jacobelli J, Pelanda R, Torres RM. LPA suppresses T cell function by altering the cytoskeleton and disrupting immune synapse formation. Proc Natl Acad Sci U S A. 2022 04 12; 119(15):e2118816119.
-
Butera A, Roy M, Zampieri C, Mammarella E, Panatta E, Melino G, D'Alessandro A, Amelio I. p53-driven lipidome influences non-cell-autonomous lysophospholipids in pancreatic cancer. Biol Direct. 2022 03 08; 17(1):6.
-
Zehra Okus F, Busra Azizoglu Z, Canatan H, Eken A. S1P analogues SEW2871, BAF312 and FTY720 affect human Th17 and Treg generation ex vivo. Int Immunopharmacol. 2022 Jun; 107:108665.
-
Corte TJ, Lancaster L, Swigris JJ, Maher TM, Goldin JG, Palmer SM, Suda T, Ogura T, Minnich A, Zhan X, Tirucherai GS, Elpers B, Xiao H, Watanabe H, Smith RA, Charles ED, Fischer A. Phase 2 trial design of BMS-986278, a lysophosphatidic acid receptor 1 (LPA1) antagonist, in patients with idiopathic pulmonary fibrosis (IPF) or progressive fibrotic interstitial lung disease (PF-ILD). BMJ Open Respir Res. 2021 Dec; 8(1).
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|